Trastuzumab, also known by its brand name Herceptin, is a monoclonal antibody used in the treatment of certain types of breast cancer. It specifically targets the human epidermal growth factor receptor 2 (HER2) protein, which is overexpressed in some cancer cells. By binding to the HER2 receptor, trastuzumab inhibits the proliferation of these cancer cells.
